DrugPatentWatch Database Preview
Otsuka Pharm Co Ltd Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for OTSUKA PHARM CO LTD, and what generic alternatives to OTSUKA PHARM CO LTD drugs are available?
OTSUKA PHARM CO LTD has five approved drugs.
There are forty-eight US patents protecting OTSUKA PHARM CO LTD drugs.
There are eight hundred and four patent family members on OTSUKA PHARM CO LTD drugs in forty-five countries and twenty-nine supplementary protection certificates in fourteen countries.
Summary for Otsuka Pharm Co Ltd
| International Patents: | 804 |
| US Patents: | 48 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Otsuka Pharm Co Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-005 | Jul 10, 2015 | RX | Yes | No | 7,888,362 | Start Trial | Y | Start Trial | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-003 | Nov 13, 2017 | RX | Yes | No | 8,580,796 | Start Trial | Y | Start Trial | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | RX | Yes | Yes | 9,258,035 | Start Trial | Y | Start Trial | |||
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-002 | Apr 23, 2018 | RX | Yes | No | Start Trial | Start Trial | |||||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-005 | Nov 13, 2017 | RX | Yes | No | 9,125,939 | Start Trial | Start Trial | ||||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-006 | Jul 10, 2015 | RX | Yes | No | 8,349,840 | Start Trial | Y | Start Trial | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-005 | Nov 13, 2017 | RX | Yes | No | 9,433,371 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Otsuka Pharm Co Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-003 | Sep 29, 2014 | 5,006,528*PED | Start Trial |
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | 5,006,528*PED | Start Trial |
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-002 | Apr 23, 2018 | 5,972,882 | Start Trial |
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-003 | Apr 23, 2018 | 5,972,882 | Start Trial |
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-002 | Feb 28, 2013 | 5,006,528*PED | Start Trial |
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-004 | Apr 23, 2018 | 5,972,882 | Start Trial |
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-004 | Sep 29, 2014 | 5,006,528*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Otsuka Pharm Co Ltd Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 103066226 | Start Trial |
| Japan | 2017225826 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007026971 | Start Trial |
| Japan | 2016517317 | Start Trial |
| Singapore | 184494 | Start Trial |
| Canada | 3030268 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2006116718 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Otsuka Pharm Co Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0450097 | CA 2009 00031 | Denmark | Start Trial | |
| 1869025 | 2018C/037 | Belgium | Start Trial | PRODUCT NAME: BREXPIPRAZOL OF EEN ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1294 20180730 |
| 1675573 | C300669 | Netherlands | Start Trial | PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115 |
| 1869025 | C201830050 | Spain | Start Trial | PRODUCT NAME: BREXPIPRAZOL O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1294; DATE OF AUTHORISATION: 20180726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1294; DATE OF FIRST AUTHORISATION IN EEA: 20180726 |
| 0450097 | 09C0049 | France | Start Trial | PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803 |
| 1869025 | PA2018509,C1869025 | Lithuania | Start Trial | PRODUCT NAME: BREKSPIPRAZOLAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/18/1294 20180726 |
| 1675573 | 92427 | Luxembourg | Start Trial | PRODUCT NAME: ARIPIPRAZOLE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
